Structure-Activity Relationship and Functional Evaluation of Cannabinoid Type-1 Receptor

Overview

Journal Biomol Ther (Seoul)

Specialty Pharmacology

Date 2024 Jun 6

PMID 38844801

Authors

Shujie Wang

Xinru Tian

Suresh Paudel

Sungho Ghil

Choon-Gon Jang

Kyeong-Man Kim

Affiliations

Soon will be listed here.

Abstract

The type-1 cannabinoid receptor (CBR) is a potential therapeutic target in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Owing to their structural diversity, it is not easy to derive general structure-activity relationships (SARs) for CBR ligands. In this study, CBR ligands were classified into six structural families, and the corresponding SAR was determined for their affinities for CBR. In addition, we determined their functional activities for the activation of extracellular signal-regulated kinases (ERKs). Among derivatives of indol-3-yl-methanone, the highest ligand affinity was observed when a pentyl and a naphthalenyl group were attached to the N1 position of the indole ring and the carbon site of the methanone moiety, respectively. In the case of adamantane indazole-3-carboxamide derivatives, the presence of fluorine in the pentyl group, the substituent at the N1 position of the indazole ring, strongly increased the affinity for CBR. For (naphthalen-1-yl) methanone derivatives, the presence of 4-alkoxynaphthalene in the methanone moiety was more beneficial for the affinity to CBR than that of a heterocyclic ring. The functional activities of the tested compounds, evaluated through ERK assay, were correlated with their affinity for CBR, suggesting their agonistic nature. In conclusion, this study provides valuable insight for designing novel ligands for CBR, which can be used to control psychiatric disorders and drug abuse.

References

Aung M, Griffin G, Huffman J, Wu M, Keel C, Yang B . Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend. 2000; 60(2):133-40. DOI: 10.1016/s0376-8716(99)00152-0. View

Bisogno T, Melck D, Bobrov MYu , Gretskaya N, Bezuglov V, De Petrocellis L . N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000; 351 Pt 3:817-24. PMC: 1221424. View

Maneuf Y, Brotchie J . Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol. 1997; 120(8):1397-8. PMC: 1564638. DOI: 10.1038/sj.bjp.0701101. View

Jarbe T, Deng H, Vadivel S, Makriyannis A . Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol. 2011; 22(5-6):498-507. PMC: 3212432. DOI: 10.1097/FBP.0b013e328349fbd5. View

Min X, Sun N, Wang S, Zhang X, Kim K . Sequestration of Gβγ by deubiquitinated arrestins into the nucleus as a novel desensitization mechanism of G protein-coupled receptors. Cell Commun Signal. 2023; 21(1):11. PMC: 9854190. DOI: 10.1186/s12964-022-01013-z. View

Calandra B, Portier M, Kerneis A, Delpech M, Carillon C, Le Fur G . Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol. 1999; 374(3):445-55. DOI: 10.1016/s0014-2999(99)00349-0. View

Hill A, Williams C, Whalley B, Stephens G . Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2011; 133(1):79-97. DOI: 10.1016/j.pharmthera.2011.09.002. View

Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K . 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995; 215(1):89-97. DOI: 10.1006/bbrc.1995.2437. View

Melck D, Bisogno T, De Petrocellis L, Chuang H, Julius D, Bifulco M . Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun. 1999; 262(1):275-84. DOI: 10.1006/bbrc.1999.1105. View

10.

Pertwee R, Howlett A, Abood M, Alexander S, Di Marzo V, Elphick M . International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev. 2010; 62(4):588-631. PMC: 2993256. DOI: 10.1124/pr.110.003004. View

11.

Matsuda L, Lolait S, Brownstein M, Young A, Bonner T . Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284):561-4. DOI: 10.1038/346561a0. View

12.

McGaraughty S, Chu K, Dart M, Yao B, Meyer M . A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors. Neuroscience. 2008; 158(4):1652-61. DOI: 10.1016/j.neuroscience.2008.11.015. View

13.

De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H . 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther. 2004; 310(2):620-32. DOI: 10.1124/jpet.103.062836. View

14.

Izzo A, Borrelli F, Capasso R, Di Marzo V, Mechoulam R . Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30(10):515-27. DOI: 10.1016/j.tips.2009.07.006. View

15.

Merrill C, Friend L, Newton S, Hopkins Z, Edwards J . Ventral tegmental area dopamine and GABA neurons: Physiological properties and expression of mRNA for endocannabinoid biosynthetic elements. Sci Rep. 2015; 5:16176. PMC: 4639757. DOI: 10.1038/srep16176. View

16.

Frost J, Dart M, Tietje K, Garrison T, Grayson G, Daza A . Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2009; 53(1):295-315. DOI: 10.1021/jm901214q. View

17.

Szabo B, Siemes S, Wallmichrath I . Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci. 2002; 15(12):2057-61. DOI: 10.1046/j.1460-9568.2002.02041.x. View

18.

Huffman J, Zengin G, Wu M, Lu J, Hynd G, Bushell K . Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem. 2004; 13(1):89-112. DOI: 10.1016/j.bmc.2004.09.050. View

19.

Sugiura T, Kodaka T, Kondo S, Tonegawa T, Nakane S, Kishimoto S . 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun. 1996; 229(1):58-64. DOI: 10.1006/bbrc.1996.1757. View

20.

Dziadulewicz E, Bevan S, Brain C, Coote P, Culshaw A, Davis A . Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem. 2007; 50(16):3851-6. DOI: 10.1021/jm070317a. View